Recent research has demonstrated that AURK inhibitors have a strong synergistic effect when combined with palbociclib in AML cells that contain FLT3-ITD and FLT3-D835Y mutations.[28] The observed synergy suggests that the combination of AURK inhibitors and palbociclib has potential as a therapeutic approach for AML treatment. The gene discussed is FLT3; the disease is acute myeloid leukemia.